retatrutide for diabetes weight loss: Study shows 30% body weight loss Retatrutide may become the most

falsely advertised its compounded GLP-1 injections as containing the same active ingredient as brand-name weight loss drugs Ozempic and Wegovy, despite differences in formulation and regulatory status

"This finding suggests that the standard fasting guidelines should suffice to mitigate any risks." The study's findings challenge the current seven-day hold recommendation, particularly for patients using GLP-1 agonists for diabetes management

Jiang, J

Investigating the effects of delaying treatment even further into the disease progression in future studies could provide more clinically relevant insights into the potential for reversing or significantly slowing down established HFpEF

SURMOUNT-2, which included participants with type 2 diabetes, showed weight reductions of 12.8% to 15.7% with tirzepatide versus 3.2% with placebo

For weight management, NICE recommends liraglutide 3mg (Saxenda) or semaglutide 2.4mg (Wegovy) for adults with a BMI of at least 35 kg/m (or 30 kg/m with weight-related comorbidities) alongside a reduced-calorie diet and increased physical activity